Skip to content

to compare two preoperatory antibiotic regimens to prevent surgical infections in colon surgery

Antibiotic prophylaxis oral vs parenteral + parenteral in colonic surgery: a prospective, randomized, multicenter clinical trial. - ATB-PROF

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2014-002345-21-ES
Enrollment
536
Registered
2014-10-03
Start date
2015-01-19
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The hypothesis of this study is that using antibiotic prophilaxis with oral antibiotic added to a standard intravenous regimen in colorectal surgery, but without the use of mechanical bowel preparation, could improve the incidence of postoperative septic complications. If this is proved, this could benefit a large number of patients, due to the high prevalence of septic complications in colon surgery, and the high morbidity and mortality associated with these. MedDRA version: 17.0 Level: PT Cla

Interventions

Product Name: CIPROFLOXACINO Pharmaceutical Form: Tablet INN or Proposed INN: CIPROFLOXACIN CAS Number: 85721-33-1 Other descriptive name: CIPROFLOXACIN Concentration unit: mg milligram(s) Concentrati

Sponsors

Dr Eloy Espin
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult patients over 18 years of age diagnosed with malignant or benign disease with indication for segmental colon resection, or total colectomy for the same indications, without medical contraindication to surgery. Patients who agree to participate voluntarily in the study and signs an informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 336 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 200

Exclusion criteria

Exclusion criteria: - Patients who refuse to participate in the study. - Patients undergoing mechanical bowel preparation the day before surgery. - Patients with intraabdominal sepsis before surgery (abscess). - Patients who received preoperative antibiotics for any reason within two weeks prior to surgery. - Patients who have allergies to study drugs. - Patients who do not comply strictly with the assigned prophylaxis regimen. - Patients that cannot be followed for at least 4 weeks after surgery.

Design outcomes

Primary

MeasureTime frame
Main Objective: This clinical trial aims to make an assessment of the effectiveness of oral and intravenous antibiotic prophylaxis in elective colon surgery, compared with administration of intravenous prophylaxis alone. The evaluation of the effectiveness is performed by the prospective recording of septic complications in the postoperative period and following the patient for one month; to determine whether the application of oral and intravenous antibiotic prophylaxis improves the incidence of surgical site infections in colonic surgery in patients who did not receive any mechanical preparation of the colon before surgery.;Secondary Objective: To evaluate the safety and tolerability of such prophylaxis regarding intravenous prophylaxis in patients not receiving mechanical preparation of the colon (comparison of complication rate, type and treatment needed and hospital length of stay between the two regimens of prophylaxis).;Primary end point(s): surgical site infection, perioperative complications: rate, type and treatment needed;Timepoint(s) of evaluation of this end point: 30 days, or during hospital stay if longer

Secondary

MeasureTime frame
Secondary end point(s): - Hospital length of stay, tolerance of treatment;Timepoint(s) of evaluation of this end point: 30 days, or during hospital stay if longer

Countries

Spain

Contacts

Public ContactColorectal Surgery Unit

Dr Eloy Espin

eespinbasany@gmail.com349342720006587

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026